Fitish RX Review: Following the Care Path From Online Intake to Pharmacy Delivery

An online prescription service is more than its intake form. Someone must review the application, decide whether treatment is appropriate, arrange dispensing, handle delivery problems and remain available afterward. Fitish RX describes a pathway connecting these steps: a virtual evaluation, medication if approved, shipping and continuing support. This documentary review follows that pathway rather than treating the advertised monthly price as the whole service. The key question is where responsibilities are documented—and where a prospective patient still needs a specific answer.

The public pages consulted October 19, 2026 describe compounded semaglutide with B6, injectable compounded tirzepatide, oral tirzepatide tablets and a separate microdosing program. They also identify different organizations involved in the business and clinical care. There is meaningful detail about prices and contact routes, but less about named dispensing pharmacies, state availability, review times and cancellation procedures. Those gaps do not prove poor service; they limit what a reader can establish before enrolling.

At a glance

Clinical organization: The privacy notice identifies Fitish, LLC and DrTelx, the affiliated professional entity whose licensed providers deliver care through the website.
Sources: [7]
Semaglutide price: Compounded semaglutide + B6 is advertised at $219 per monthly supply, including consultation, medication if approved and shipping, without separate consultation or membership fees.
Sources: [8]
Tirzepatide options: Compounded injectable tirzepatide and oral tirzepatide tablets are each advertised at $339 per monthly supply, with evaluation and a prescription required.
Sources: [14] [11]
Follow-up: Fitish RX advertises check-ins, progress tracking and care-team messaging; its injectable tirzepatide page describes portal support and clinician-directed adjustments at no added cost.
Sources: [5] [14]
Payment model: Fitish RX describes itself as cash-pay and says it does not accept insurance. Bundle payment schedules and specific cancellation or refund terms remain unclear in the consulted documentation.
Sources: [5] [8] [14] [9]

Start by identifying who delivers the care

Fitish RX calls itself a telehealth wellness clinic, while its terms identify FITISH as the website operator. The health privacy notice adds an important distinction: it is provided by Fitish, LLC together with DrTelx, described as the affiliated professional entity whose licensed providers deliver care through fitishrx.com. That separates the consumer-facing brand from the organization identified with clinical services. It does not independently verify an individual clinician’s credentials or establish who would review a particular application.

The advertised encounter takes place from home through a virtual evaluation, without an in-person visit. A prescription follows only if clinically appropriate. The documentation does not establish that every applicant sees a physician, nor does it identify whether a particular evaluation uses video, telephone or written communication. Before paying, a useful question is which licensed clinician will take responsibility for the evaluation and how that clinician can be reached afterward.

Geography is another unresolved part of this organizational picture. The terms reserve the ability to restrict sales by person, region or jurisdiction, but the consulted pages do not provide a state-by-state service list. A Fort Worth mailing address is not evidence of nationwide clinical availability. Our guide to the clinician-platform distinction explains why confirming the treating organization and service state matters separately from recognizing the website’s brand.

Sources: [13] [7] [9] [5] [10]

What happens between the intake form and a prescription

The semaglutide page describes a short online intake covering health and goals, followed by review by a licensed provider. If the clinician finds semaglutide appropriate, a prescription is written. For weight management, Fitish RX says applicants must be adults whose BMI and medical history satisfy clinical eligibility criteria. It says every intake is reviewed before prescribing. Its privacy policy separately states that it does not knowingly provide services to people younger than 18.

The consulted documentation does not supply numeric BMI thresholds, a complete screening protocol or laboratory requirements. It also does not state how quickly an intake will be reviewed, whether additional records might be needed or what happens financially when a prescription is declined. Consequently, neither completing the form nor choosing a displayed package should be read as approval. Ask when payment is collected relative to clinical review and what charges remain if treatment is not prescribed.

Preparation can make that review more useful without attempting to decide eligibility yourself. NIDDK advises discussing medicines, supplements, allergies and pregnancy plans with the treating clinician, alongside health conditions and treatment costs. Our first-consultation preparation guide offers a framework for organizing those questions. Fitish RX’s abbreviated public eligibility description is a reason to request its actual evaluation requirements, not a basis for assuming that a general BMI threshold guarantees access.

Sources: [5] [14] [12] [8] [2]

The prescription needs to identify the actual formulation

Fitish RX’s offerings should not be collapsed into one generic GLP-1 plan. Its semaglutide listing specifies a compounded preparation with B6. Its compounded tirzepatide page describes subcutaneous injection under clinician management. A separate page advertises oral tirzepatide tablets for adults who prefer an oral option and meet clinical criteria. These distinctions matter at the prescribing and dispensing stages: the ingredient name alone does not identify the route, formulation or instructions a patient will receive.

The oral page explicitly states that compounded oral tirzepatide is not FDA approved and that there is no FDA-approved oral tirzepatide product. It distinguishes this offering from approved injectable tirzepatide. The semaglutide page likewise acknowledges that compounded medications lack FDA approval and FDA review for safety, effectiveness and manufacturing quality. Mentioning an approved commercial product as an alternative does not establish that Fitish RX actually dispenses it; that offering was not documented in the consulted material.

FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not demonstrate clinical inequivalence, but it also does not establish that an oral preparation, vitamin blend or other formulation shares the evidence for an approved product. Our formulation-check guide focuses on the practical next step: obtain the exact product description and pharmacy information rather than relying on an ingredient-level comparison.

Sources: [8] [14] [11] [1]

What the advertised payment includes—and what bundles do not explain

Fitish RX describes a cash-pay service that does not accept insurance. Its standard semaglutide price is $219 for a monthly supply; injectable and oral tirzepatide are each $339 for a monthly supply. Each listing includes consultation, medication if approved and shipping. The semaglutide and injectable tirzepatide pages expressly say there are no separate consultation or membership fees. The oral page confirms the included components, but its quoted pricing statement does not separately make that same no-membership-fee declaration.

Three- and six-month bundles are advertised for all three standard offerings, with pricing applied during intake. Fitish RX labels the respective discounts as 10% and 20%; those are provider-advertised claims, not independently recalculated savings here. Crucially, a monthly figure attached to a bundle does not explain whether payment is collected monthly or upfront. Nor does the package duration establish the quantity dispensed at once, a minimum commitment or the consequences of leaving early.

The table separates the stated supply periods because the microdosing page uses different language from the standard plans. Beyond these advertised inclusions, the consulted pages do not clarify whether laboratory work, administration supplies or external services carry additional costs. The terms also say prices may change without notice. Request a written checkout breakdown showing the first charge, subsequent billing interval and any bundle payment obligation before treating the displayed monthly amount as the complete payment arrangement.

Advertised prices; prescriptions and medical evaluation are required. Bundle collection schedules are not established.
Offering	Standard advertised price	Bundle or period detail
Compounded semaglutide + B6	$219 per monthly supply	Three months: $195/month; six months: $175/month
Compounded subcutaneous tirzepatide	$339 per monthly supply	Three months: $305/month; six months: $270/month
Oral tirzepatide tablets	$339 per monthly supply	Three months: $305/month; six months: $270/month
Microdosing semaglutide	$179 per 28-day supply in detailed pricing	Page also uses monthly language; no additional discounts
Microdosing tirzepatide	$269 per 28-day supply in detailed pricing	Page also uses monthly language; no additional discounts

Sources: [8] [14] [11] [15] [5] [9]

The pharmacy handoff and delivery remain less specific

The injectable tirzepatide page says medication ships discreetly from a licensed compounding pharmacy on a monthly cadence. The semaglutide page describes preparation by a state-licensed sterile compounding pharmacy. These are provider statements about the pharmacy arrangement, not independent license checks. The consulted material does not name the dispensing pharmacies or provide their license details. That leaves readers unable to identify in advance which pharmacy would prepare, dispense and answer questions about their particular prescription.

A monthly shipping cadence is not an arrival guarantee. Fitish RX’s public documentation does not establish clinical-review turnaround, preparation time, dispatch timing or transit duration. It also does not specify the carrier, tracking arrangements or refrigeration conditions. Ask when the pharmacy receives the prescription, when tracking becomes available and whom to contact if shipment is delayed. Those questions distinguish a clinical approval from a parcel actually leaving the pharmacy and ultimately reaching the patient.

For damaged, defective or incorrect orders, Fitish RX directs patients to theclinic@fitish.com, but the quoted contact language does not promise a particular replacement or refund remedy. For injectable GLP-1 medication arriving warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. Our cold-chain guidance explains that advice. Included shipping should therefore be evaluated alongside the delivery-problem process, not mistaken for a complete description of fulfillment responsibilities.

Sources: [14] [8] [10] [1]

Portal follow-up is advertised, but response standards are not

Fitish RX says patients receive regular check-ins, progress tracking and direct messaging with the care team. Its injectable tirzepatide page adds that the team remains available through the patient portal for questions, clinician-directed adjustments and ongoing support at no added cost. This is a meaningful description of continuing care rather than a prescription-only transaction. Nevertheless, the consulted pages do not explain the check-in schedule, who answers each type of message or whether patients retain continuity with the original prescriber.

The contact page supplies several separate routes: theclinic@fitish.com for treatment and product questions, orders@fitish.com for orders and existing patients, and info@fitish.com for general inquiries. It also publishes 1-800-576-8990. These distinctions can help route an issue, but no documented hours or response deadlines establish round-the-clock clinical access. Before starting, ask how urgent concerns are handled and whether portal messages are reviewed by clinical staff or first triaged by administrative support.

Ongoing care should address response and tolerability, not simply the next shipment. NIDDK describes follow-up in those terms, and FDA has reported measuring or administration errors involving compounded GLP-1 drugs, some associated with hospitalization. Instructions should be clarified with the prescriber or pharmacist rather than reconstructed from a review. Fitish RX’s privacy notice also recognizes a right to inspect and obtain health records, including an electronic copy where readily producible, subject to exceptions and a possible reasonable cost-based fee.

Sources: [5] [14] [10] [7] [2] [1]

Microdosing is presented as a different program

Fitish RX’s microdosing page expressly describes that program as intended for general wellness and cosmetic support, not weight loss or weight management. Elsewhere, its GLP-1 pages suggest that some applicants below the standard program’s BMI threshold might be candidates after clinical review. Those statements create a practical distinction to resolve during intake: which program is being considered, for what stated purpose, and why the clinician considers it appropriate. The alternative pathway is not a documented promise of eligibility.

The price description also needs clarification. The page initially advertises the program from $179 with monthly-supply language, then specifies $179 for semaglutide and $269 for tirzepatide per 28-day supply. Twenty-eight days and a calendar month are different intervals. Fitish RX says this program is already discounted and excludes additional discounts. Readers should obtain the actual supply duration and charge frequency rather than applying the standard plans’ monthly language or bundle offers to this separate program.

Fitish RX’s marketing references metabolic, appetite and longevity benefits when discussing this option, but those claims are not established by the clinical material consulted here. STEP 1 and SURMOUNT-1 were not trials of Fitish RX, its compounded preparations or its microdosing program. Their findings cannot be transferred to this service as measured outcomes. The useful care-delivery question is what evidence and follow-up plan the treating clinician uses for the specific proposed formulation and purpose.

Sources: [15] [14] [3] [4]

Stopping service requires more than leaving the website

Fitish RX’s general terms say a user may terminate the agreement by notifying the company that they no longer wish to use the services or by ceasing to use the site. That language does not specify how to stop future clinical shipments or charges. Likewise, the SMS policy allows a recipient to reply STOP and receive a final confirmation message. That is cancellation of text messaging, not documented cancellation of medication services, billing or an outstanding bundle obligation.

The consulted documentation does not establish automatic-renewal rules, charge dates, cancellation deadlines, pause procedures or refunds for unused supplies or clinical denial. The terms refer returns and exchanges to a Return Policy, but that policy was not available in the consulted material. Cancellation should not be assumed to produce a refund. A useful pre-enrollment request is a written explanation of the exact cancellation channel, when a request takes effect and what happens to an order already being prepared.

There is also a clinical handoff to consider when leaving. NIDDK notes that treatment duration depends on response and side effects and that obesity may require long-term care; continued results after stopping cannot be promised. Fitish RX’s record-access provision may help with continuity, but the public pages do not describe a transfer-of-care process. Ask how to obtain the current medication record, pharmacy details and relevant visit information while separately resolving any final financial obligations.

Sources: [9] [6] [7] [2]

Questions & answers

Does Fitish RX guarantee a prescription after I complete intake?

No. Its pages describe review by a licensed provider and prescribing only when clinically appropriate. The semaglutide intake asks about health and goals; the weight-management program also refers to BMI and medical-history criteria. The consulted documentation does not establish how charges are handled after a clinical denial, so confirm that before payment.

Sources: [5] [8] [14]

Are the three- and six-month bundles necessarily prepaid?

The consulted pages do not establish that. They advertise monthly amounts for three- and six-month bundles and say bundle pricing is applied during intake. They do not explain the collection schedule, total initially due or any minimum commitment. Request those terms in writing rather than assuming either upfront payment or ordinary month-to-month billing.

Sources: [8] [14] [11]

Can I use insurance for Fitish RX’s advertised plans?

Fitish RX says it does not accept insurance and operates as a cash-pay telehealth service. The advertised plan price should therefore be evaluated as a direct payment, not an insurance copayment. The consulted pages do not establish reimbursement arrangements, and the service’s insurance policy should not be confused with an individual insurer’s coverage for medication obtained elsewhere.

Sources: [5] [2]

Which pharmacy will fill my Fitish RX prescription?

The consulted documentation does not identify dispensing pharmacies by name. Fitish RX describes a licensed compounding pharmacy for injectable tirzepatide and a state-licensed sterile compounding pharmacy for semaglutide. Ask for the pharmacy’s name, contact information and relevant license details, along with confirmation of the formulation it will dispense. These descriptions were not independently verified.

Sources: [14] [8]

Who should I contact about an incorrect or damaged delivery?

Fitish RX directs product issues, including damaged, defective or incorrect orders, to theclinic@fitish.com. Its contact page also lists orders@fitish.com for orders and existing patients. The documentation does not promise a specific refund or replacement. If an injectable GLP-1 arrives warm or inadequately refrigerated, FDA advises not using it and contacting the provider or dispensing pharmacy.

Sources: [10] [1]

Does replying STOP cancel treatment or future payments?

The documented STOP instruction cancels the SMS service only. It does not establish that clinical services, shipments or payments stop. The general website-termination language also lacks a specific billing cancellation procedure. Ask Fitish RX for the correct cancellation route, effective date and treatment of pending orders, and retain written confirmation rather than relying on a text-message unsubscribe.

Sources: [6] [9]

Our assessment

Fitish RX documents a recognizable care pathway: adult intake, clinician review, conditional prescribing, pharmacy shipping and portal follow-up. Its standard prices identify several included services, and its contact page provides distinct routes for clinical, order and general questions. The principal limitations concern the handoffs: the named prescriber and pharmacy, state availability, delivery standards, response times and the financial process for leaving. Its separate oral and microdosing offerings also require formulation-specific discussion rather than assumptions drawn from injectable-drug research. Before enrolling, obtain written confirmation of the actual prescription pathway, first and subsequent charges, dispensing pharmacy and cancellation process. Those answers would make the service more assessable than the public documentation alone allows.

Visit Fitish RX’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

FOLLOW THE EVIDENCE

Research behind treatment claims

Use these studies to assess the type of outcome a treatment claim describes. They did not test this provider or establish results for its products.

SURMOUNT-5: What a Direct Weight-Loss Comparison Can—and Cannot—Tell You About Ongoing Care
Tirzepatide produced greater average weight and waist reductions than semaglutide over 72 weeks. Understanding the trial’s design matters just as much as understanding the difference.
After the Weight Loss: What SURMOUNT-4 Means for Continuity of Care
Randomized tirzepatide withdrawal separates maintaining a treatment effect from finishing a course. Reading its two baselines—and newer maintenance-dose research—shows what the evidence can and cannot tell patients changing care.

Explore the science library →

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Fitish RX Review: Following the Care Path From Online Intake to Pharmacy Delivery

At a glance

01Start by identifying who delivers the care

02What happens between the intake form and a prescription

03The prescription needs to identify the actual formulation

04What the advertised payment includes—and what bundles do not explain

05The pharmacy handoff and delivery remain less specific

06Portal follow-up is advertised, but response standards are not

07Microdosing is presented as a different program

08Stopping service requires more than leaving the website